UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
(Mark One)
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from __________ to ____________
Commission File Number:
STREAMLINE HEALTH SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| | | |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | | Smaller reporting company |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
The number of shares outstanding of the Registrant’s Common Stock, $0.01 par value per share, as of June 10, 2024, was
| Page |
||
| Part I. |
||
| Item 1. |
||
| Condensed Consolidated Balance Sheets at April 30, 2024 (unaudited) and January 31, 2024 |
||
| Notes to Unaudited Condensed Consolidated Financial Statements |
||
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
| Item 3. |
||
| Item 4. |
||
| Part II. |
||
| Item 1A. |
||
| Item 2. |
||
| Item 6. |
||
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
STREAMLINE HEALTH SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(rounded to the nearest thousand dollars, except share and per share information)
| April 30, 2024 | January 31, 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net of allowance for credit losses of $ and $, respectively | ||||||||
| Contract receivables | ||||||||
| Prepaid and other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Property and equipment, net of accumulated amortization of $ and $ respectively | ||||||||
| Capitalized software development costs, net of accumulated amortization of $ and $, respectively | ||||||||
| Intangible assets, net of accumulated amortization of $ and $, respectively | ||||||||
| Goodwill | ||||||||
| Other | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
STREAMLINE HEALTH SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(rounded to the nearest thousand dollars, except share and per share information)
| April 30, 2024 |
January 31, 2024 |
|||||||
| (Unaudited) |
||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | $ | ||||||
| Accrued expenses |
||||||||
| Current portion of term loan |
||||||||
| Deferred revenues |
||||||||
| Acquisition earnout liability |
||||||||
| Total current liabilities |
||||||||
| Non-current liabilities: |
||||||||
| Term loan, net of current portion and deferred financing costs |
||||||||
| Line of credit |
||||||||
| Notes payable, net of current portion and deferred financing costs |
||||||||
| Warrants – common stock |
||||||||
| Deferred revenues, less current portion |
||||||||
| Total non-current liabilities |
||||||||
| Total liabilities |
||||||||
| Commitments and contingencies – Note 8 |
||||||||
| Stockholders’ equity: |
||||||||
| Common stock, $0.01 par value per share, 85,000,000 shares authorized; 61,825,587 and 58,945,498 shares issued and outstanding, respectively |
||||||||
| Additional paid in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| Total stockholders’ equity |
||||||||
| Total liabilities and stockholders’ equity |
$ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
| Three Months Ended April 30, | ||||||||
| 2024 | 2023 | |||||||
| Revenues: | ||||||||
| Software as a service | $ | $ | ||||||
| Maintenance and support | ||||||||
| Professional fees and licenses | ||||||||
| Total revenues | ||||||||
| Operating expenses: | ||||||||
| Cost of software as a service | ||||||||
| Cost of maintenance and support | ||||||||
| Cost of professional fees and licenses | ||||||||
| Selling, general and administrative expense | ||||||||
| Research and development | ||||||||
| Total operating expenses | ||||||||
| Operating loss | ( | ) | ( | ) | ||||
| Other (expense) income: | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Valuation adjustments | ( | ) | ||||||
| Other | ||||||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Income tax expense | ( | ) | ||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Basic and Diluted Earnings Per Share: | ||||||||
| Net loss per common share – basic and diluted | $ | ( | ) | $ | ( | ) | ||
| Weighted average number of common shares – basic and diluted | ||||||||
See accompanying notes to condensed consolidated financial statements.
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(rounded to the nearest thousand dollars, except share information)
| Additional | Total | |||||||||||||||||||
| Common stock | Common stock | paid in | Accumulated | stockholders’ | ||||||||||||||||
| (Shares) | (Amount) | capital | deficit | equity | ||||||||||||||||
| Balance at January 31, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Restricted stock issued | ( | ) | ||||||||||||||||||
| Restricted stock forfeited | ( | ) | ||||||||||||||||||
| Surrender of shares | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Share-based compensation | — | |||||||||||||||||||
| Issuance of common stock | ||||||||||||||||||||
| Offering expenses | — | ( | ) | ( | ) | |||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||
| Balance at April 30, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Additional | Total | |||||||||||||||||||
| Common stock | Common stock | paid in | Accumulated | stockholders’ | ||||||||||||||||
| (Shares) | (Amount) | capital | deficit | equity | ||||||||||||||||
| Balance at January 31, 2023 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Restricted stock issued | ( | ) | ||||||||||||||||||
| Restricted stock forfeited | ( | ) | ( | ) | ||||||||||||||||
| Surrender of shares | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Share-based compensation | — | |||||||||||||||||||
| Adoption of ASU 2016-13 | ||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||
| Balance at April 30, 2023 | $ | $ | $ | ( | ) | $ | ||||||||||||||
See accompanying notes to condensed consolidated financial statements.
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(rounded to the nearest thousand dollars)
| Three Months Ended April 30, | ||||||||
| 2024 | 2023 | |||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Accrued interest expense – notes payable | ||||||||
| Valuation adjustments | ( | ) | ||||||
| Benefit for deferred income taxes | ||||||||
| Share-based compensation expense | ||||||||
| Changes in assets and liabilities: | ||||||||
| Accounts and contract receivables | ||||||||
| Other assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses and other liabilities | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | ( | ) | ||||||
| Capitalization of software development costs | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repayment of bank term loan | ( | ) | ( | ) | ||||
| Repayment of line of credit | ( | ) | ||||||
| Proceeds from issuance of common stock | ||||||||
| Proceeds from notes payable | ||||||||
| Payments of acquisition earnout liabilities | ( | ) | ||||||
| Payments for deferred financing costs | ( | ) | ||||||
| Payments related to settlement of employee share-based awards | ( | ) | ( | ) | ||||
| Net cash (used in) provided by financing activities | ( | ) | ||||||
| Net (decrease) increase in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
STREAMLINE HEALTH SOLUTIONS, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
April 30, 2024
NOTE 1 — BASIS OF PRESENTATION
Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its Coding & Clinical Documentation Improvement (CDI) solutions, eValuator coding analysis platform, RevID, and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle.
The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. The condensed consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries. In the opinion of the Company’s management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent annual report on Form 10-K. Operating results for the three months ended April 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2025.
The Company has operating segment and reporting unit due to the singular nature of our products, product development and distribution process, and client base as a provider of computer software-based solutions and services for acute-care healthcare providers.
All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year.
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Our significant accounting policies are presented in “Note 2 – Significant Accounting Policies” in the Annual Report on Form 10-K for fiscal year 2023. Users of financial information for interim periods are encouraged to refer to the notes to the consolidated financial statements contained in the Annual Report on Form 10-K when reviewing interim financial results.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.
Reclassification
Certain amounts for the three months ended April 30, 2023, were reclassified to conform to the current period classification. For the three months ended April 30, 2023, the Company incurred acquisition-related costs totaling $
Fair Value of Financial Instruments
The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The acquisition earnout liability transferred out of Level 3 as of three months ended April 30, 2024.
The table below provides information on the fair value of our liabilities:
| Quoted | Significant | |||||||||||||||
| Prices in | Other | Significant | ||||||||||||||
| Active | Observable | Unobservable | ||||||||||||||
| Total Fair | Markets | Inputs | Inputs | |||||||||||||
| Value | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
| At January 31, 2024 | ||||||||||||||||
| Acquisition earnout liability (1) | $ | $ | $ | $ | ||||||||||||
| At April 30, 2024 | ||||||||||||||||
| Warrants - common stock (2) | $ | $ | $ | $ | ||||||||||||
| (1) | On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. As of that date, the Company recorded a valuation adjustment of $
| |
| (2) | The fair value of the common stock warrants issued in connection with the Company’s equity raises in February 2024 is established as of the date of issuance and updated as of April 30, 2024. The change in the fair value of the common stock warrants decreased by $
The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike pries of $ | |
The table below provides the Level 3 roll-forward on the fair value of our acquisition earnout liability for the three months ended April 30, 2024:
| 3 months ended | ||||
| 04/30/2024 | ||||
| Beginning balance | $ | |||
| Settlement – common stock | ( | ) | ||
| Settlement – cash | ( | ) | ||
| Unrealized loss | ||||
| Transfer out | ( | ) | ||
| Ending balance | $ | |||
| Amount of unrealized loss for the period included in income relating to the acquisition earnout liability at the end of the period | $ | ( | ) | |
The value of the Company’s acquisition earnout liability at April 30, 2024 represents the remaining cash obligation of $
The fair value of the Company’s term loan and outstanding balance of the revolving line of credit under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) to the date of the most recent balance sheets, April 30, 2024 and January 31, 2024. The term loan bears interest at a per annum rate equal to the Rate (as published in The Wall Street Journal) plus
Revenue Recognition
We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third-party resellers. Licensed, locally-installed customers on a perpetual model utilize the Company’s support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services and consulting services.
We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, under the core principle of recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
Disaggregation of Revenue
The following table provides information about disaggregated revenue by type and nature of revenue stream:
| Three Months Ended | ||||||||
| April 30, 2024 | April 30, 2023 | |||||||
| Over time revenue | $ | $ | ||||||
| Point in time revenue | ||||||||
| Total revenue | $ | $ | ||||||
The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue.
Contract Receivables and Deferred Revenues
The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. The Company’s contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. During the three months ended April 30, 2024, the Company recognized approximately $
Deferred costs (costs to fulfill a contract and contract acquisition costs)
The Company defers the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of April 30, 2024 and January 31, 2024, the Company had deferred costs of $
Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one year or less.
As of April 30, 2024 and January 31, 2024, deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $
Allowance for Credit Losses
The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows:
| January 31, 2024 | CECL Adoption | Provision adjustments | Write-offs & Recoveries | April 30, 2024 | ||||||||||||||||
| Allowance for credit losses | $ | $ | $ | $ | $ | |||||||||||||||
| January 31, 2023 | CECL Adoption | Provision adjustments | Write-offs & Recoveries | April 30, 2023 | ||||||||||||||||
| Allowance for credit losses | $ | $ | ( | ) | $ | $ | $ | |||||||||||||
Equity Awards
The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three months ended April 30, 2024 and 2023, of $
The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.
The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three months ended April 30, 2024 and 2023, the Company issued
Warrants
The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) to account for the warrants as either equity-classified or liability-classified instruments. This review identifies if the warrants are freestanding financial instruments under ASC 480, should be defined as a liability under ASC 480, and whether the warrants meet all requirements of ASC 815 to be classified as equity, including whether the warrants are indexed to the Company’s own common stock, if there are conditions where warrant holders could potentially require “net cash settlement” in a circumstance that would be outside of the Company’s control, among other conditions for equity classification. This assessment requires the use of professional judgment and is conducted at the time of warrant issuance plus as of each subsequent quarterly period end date while the warrants are outstanding.
For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated Statements of Operations as "valuation adjustments." The fair value of the warrants is estimated using a Black-Scholes pricing model.
The Company issued warrants to purchase shares of common stock as part of the Securities Purchase Agreement. Based on the previously noted guidance, the Company determined that warrants issued in with the Securities Purchase Agreement should be recorded and accounted for as a liability as of April 30, 2024. The Company reports the fair value of the liability as non-current liabilities under the heading "Warrants – common stock" on the condensed consolidated Balance Sheet. The Company recorded an opening warrant liability of $
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. Refer to Note 6 – Income Taxes for further details.
The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. The Company believes it has appropriately accounted for any uncertain tax positions as of April 30, 2024.
Net Loss Per Common Share
The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock.
The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term or while unexercised. Diluted EPS for the Company’s common stock is computed using the treasury stock method.
The following is the calculation of the basic and diluted net loss per share of common stock for the three months ended April 30, 2024 and 2023:
| Three Months Ended | ||||||||
| April 30, 2024 | April 30, 2023 | |||||||
| Basic and diluted loss per share: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Basic and diluted net loss per share of common stock | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares outstanding – basic and diluted (1)(2) | ||||||||
| (1) | Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of April 30, 2024 and 2023, there were |
|
| |
| (2) | Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three months ended April 30, 2024, diluted earnings per share excludes |
Restructuring
On October 16, 2023, the Company announced it was executing a strategic restructuring (the "Strategic Restructuring") designed to reduce expenses while maintaining the Company’s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting in the termination of
| (in thousands) | ||||||||||||||||||||||||
| As of April 30, 2024 | ||||||||||||||||||||||||
| Accrued Balance as of | 2024 | 2024 | Accrued Balance as of | Total Costs | Total | |||||||||||||||||||
| January 31, 2024 | Expenses to Date | Cash Payments | April 30, 2024 | Incurred to Date | Expected Costs | |||||||||||||||||||
| Severance expense | ||||||||||||||||||||||||
| Cost of sales | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Selling, general, and administrative | ( | ) | ||||||||||||||||||||||
| Research and development | ||||||||||||||||||||||||
| Total severance expense | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||
| Professional fees | ||||||||||||||||||||||||
| Total | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||
Non-Cash Items
For the three months ended April 30, 2024 and 2023, the Company recorded a change in capitalized software purchased with stock, totaling $
For the three months ended April 30, 2024, the Company settled the second earnout with the issuance of common shares in the amount of $
Recent Accounting Pronouncements Not Yet Adopted
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves guidance around the disclosures about a public entity’s reportable segments and additional details about a reportable segment’s expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company’s adoption of ASU 2023-07 will be effective in the annual report for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.
NOTE 3 — BUSINESS COMBINATION
Avelead Acquisition
The Company acquired all the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021.
As of January 31, 2024, the estimated aggregate value of the second year earnout consideration was $
NOTE 4 — OPERATING LEASES
We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has moved to a virtual office model and does not have a physical office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the costs expensed as incurred. For the three months ended April 30, 2024 and 2023, the Company recorded $
Alpharetta Office Lease
On October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia. The sublease term was for
The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. The lease terminated on March 31, 2023. At inception, the Company recorded a right-of use asset of $
Suwanee Office Lease
Upon acquiring Avelead on August 16, 2021 (refer to Note 3 – Business Combination), the Company assumed an operating lease agreement for the corporate office space of Avelead. The lessor is an entity controlled by one of the Sellers and that Seller is a former employee of the Company. The initial
NOTE 5 — DEBT
Outstanding principal balances consisted of the following at April 30, 2024:
| April 30, 2024 | January 31, 2024 | |||||||
| Term loan | $ | $ | ||||||
| Financing cost payable | ||||||||
| Less: Deferred financing cost | ) | ) | ||||||
| Total | ||||||||
| Less: Current portion of term loan | ) | ) | ||||||
| Non-current portion of term loan | $ | $ | ||||||
| April 30, 2024 | January 31, 2024 | |||||||
| Notes payable | $ | $ | ||||||
| Less: Discount on notes payable | ( | ) | ||||||
| Less: Deferred financing costs | ) | |||||||
| Total | ||||||||
| Less: Current portion of notes payable | ||||||||
| Non-current portion of notes payable | $ | $ | ||||||
Term Loan and Revolving Line of Credit
On November 29, 2022, the Company executed a Second Modification to Second Amended and Restated Loan Agreement (the “Second Modification”). The Second Modification includes an expansion of the Company’s total borrowing to include a $
Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $
The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 and April 5, 2024, respectively (collectively, the “Third and Fourth Modifications”). The Third and Fourth Modifications reestablished the customary financial covenants for the Second Amended and Restated Loan Agreement as follows:
| ● | Minimum Adjusted EBITDA. Commencing with the quarter ending January 31, 2024, the Company shall maintain Adjusted EBITDA, measured on a quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set forth in parentheses, no worse than the amounts) set forth under the heading “Minimum Adjusted EBITDA” as of, and for each of the dates appearing adjacent to such “Minimum Adjusted EBITDA.” |
| Minimum | ||||
| Quarter Ending | Adjusted EBITDA | |||
| January 31, 2024 | $ | ( | ) | |
| April 30, 2024 | ( | ) | ||
| July 31, 2024 | ( | ) | ||
| October 31, 2024 | ( | ) | ||
| January 31, 2025 | ||||
| ● | Maximum ARR Net Leverage Ratio. The Company's ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal quarter, shall not be greater than the amount set forth under the heading “Maximum ARR Net Leverage Ratio” as of, and for each of the dates appearing adjacent to such “Maximum ARR Net Leverage Ratio.” |
| Maximum | |||||
| ARR Net Leverage | |||||
| Quarter Ending | Ratio | ||||
| April 30, 2024 | to | ||||
| July 31, 2024 | to | ||||
| October 31, 2024 | to | ||||
| January 31, 2025 | to | ||||
| ● | Maximum Debt to Adjusted EBITDA Ratio. Commencing with the quarter ending April 30, 2025, the Company's Maximum Debt to Adjusted EBITDA Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended, shall not be greater than the amount set forth under the heading “Maximum Debt to Adjusted EBITDA Ratio” as of, and for each of the dates appearing adjacent to such “Maximum Debt to Adjusted EBITDA Ratio.” |
| Maximum | |||||
| Debt to Adjusted | |||||
| EBITDA | |||||
| Quarter Ending | Ratio | ||||
| April 30, 2025 | to | ||||
| July 31, 2025 | to | ||||
| October 31, 2025 | to | ||||
| January 31, 2026 and on the last day of each quarter thereafter | to | ||||
| ● | Fixed Charge Coverage Ratio. Commencing with the quarter ending April 30, 2025, the Company shall maintain a Fixed Charge Coverage Ratio of not less than |
The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. As of April 30, 2024, the Company was in compliance with the Second Amended and Restated Loan Agreement covenants.
The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $
Debt Private Placement
On February 1, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the “Notes”) in the aggregate principal amount of $
Notes Payable
The Notes bear interest at a rate of
The Notes also include customary negative covenants, subject to exceptions, which limit dispositions of assets and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default.
The rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (“WAB”), pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.
The Company allocated the original total proceeds at inception from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with the offerings. The Company has recorded the Notes at a relevant residual fair value of $
Warrants
The Warrants have an exercise price of $
The Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the Common Stock underlying the Warrants, were "restricted securities" under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the Common Stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to “accredited investors” as that term is defined in Rule 501(a) under the Securities Act.
The Warrants contain a registration rights provision for the Company to provide the Warrant holder with registered Common Stock upon their exercise of a Warrant. If the Company is not able to deliver registered Common Stock for exercised Warrants that results in the Warrant holder acquiring registered Common Stock, then the Warrant holder has the discretion to request the Company remit cash compensation up to the corresponding purchase price. Accordingly, the Company determined the feature required liability accounting treatment. On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024, for purpose of registering for resale
The Company allocated the total proceeds from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with offerings. The Company recorded an initial liability of $
NOTE 6 — INCOME TAXES
Income tax was $
The Company has recorded $
The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2019. All material state and local income tax matters have been concluded for years through January 31, 2018. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2019; however, carryforward losses that were generated prior to the tax year ended January 31, 2019, may still be adjusted by the IRS if they are used in a future period.
NOTE 7 — EQUITY
Common Stock Private Placement
On February 6, 2024, the Company completed the sale of
The common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The Common Stock was offered and sold to an “accredited investor” as that term is defined in Rule 501(a) under the Securities Act.
The Company allocated the total proceeds of the Common Stock Private Placement across the underlying components. As a result, $
Registration of Shares Issued to 180 Consulting
On June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purpose of registering for resale
On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024, for purpose of registering for resale
Authorized Shares Increase
At the Annual Meeting of Stockholders held on June 15, 2023, the Company’s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan to increase the available number of shares of the Company’s common stock authorized for issuance thereunder by
NOTE 8 — COMMITMENTS AND CONTINGENCIES
Consulting Agreement with 180 Consulting, LLC
On March 19, 2020, the Company entered into a Master Services Agreement (the “MSA”) with 180 Consulting, pursuant to which 180 Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among others, through separate executed statements of work (“SOWs”). On September 20, 2021, the Company entered into a separate MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs. As of April 30, 2024, there were three active SOWs under the eValuator MSA. One of the active SOWs includes the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in this MSA or the related SOWs, individuals providing services to the Company under the MSA and the SOWs may share workspace and administrative costs with 121G Consulting, LLC (“121G”). Mr. Green is a “member” of 121G, and, accordingly, has a financial interest in that entity. 180 Consulting earned
Inclusive of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense software through 180 Consulting that is owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our clients’ technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180 Consulting licenses the software from 121G at cost. The Company paid approximately $
NOTE 9 - RELATED PARTY TRANSACTIONS
Avelead Office Lease
The Company acquired Avelead on August 16, 2021. Accordingly, the Company assumed a lease for corporate office space from one of the selling shareholders of Avelead who was employed by the company through August 2023. This lease term ended February 2023. For the three months ended April 30, 2024 and 2023, the Company recorded rent expense of $
Debt Private Placement
On February 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes in the aggregate principal amount of $
| Name of Investor | Investment Amount | Warrants Granted | ||||||
| 121G, LLC (1) | $ | |||||||
| Matthew Etheridge (2) | ||||||||
| Jonathan R. Phillips (3) | ||||||||
| The Ferayorni Family Trust (4) | ||||||||
(1) The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.
(2) Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.
(3) Mr. Phillips is a member of the Company’s Board of Directors.
(4) The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.
Common Stock Private Placement
On February 6, 2024, the Company completed the sale of
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING STATEMENTS
We make forward-looking statements in this Quarterly Report on Form 10-Q (this “Report”) and in other materials we file with the SEC or otherwise make public. This Report, therefore, contains statements about future events and expectations which are forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933, as amended (the “Securities Act”), and 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, our senior management makes forward-looking statements to analysts, investors, the media and others. Statements with respect to expected revenue, income, receivables, backlog, client attrition, acquisitions and other growth opportunities, sources of funding operations and acquisitions, the integration of our solutions, the performance of our channel partner relationships, the sufficiency of available liquidity, research and development, and other statements of our plans, beliefs or expectations are forward-looking statements. These and other statements using words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would” and similar expressions also are forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement. The forward-looking statements we make are not guarantees of future performance, and we have based these statements on our assumptions and analyses in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. Forward-looking statements by their nature involve substantial risks and uncertainties that could significantly affect expected results, and actual future results could differ materially from those described in such statements. Management cautions against putting undue reliance on forward-looking statements or projecting any future results based on such statements or present or historical earnings levels.
Among the factors that could cause actual future results to differ materially from our expectations are the risks and uncertainties described under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 and in our subsequent filings with the SEC, and include among others, the following:
| ● |
competitive products and pricing; |
|
|
|
||
| ● |
product demand and market acceptance; |
|
|
|
||
| ● |
entry into new markets; |
|
|
|
||
| ● |
the possibility that any of the anticipated benefits of the acquisition of Avelead Consulting, LLC (“Avelead”) will not be realized or will not be realized within the expected time period, the businesses of the Company and the Avelead segment may not be integrated successfully, or such integration may be more difficult, time-consuming or costly than expected, or revenues following the Avelead acquisition may be lower than expected; |
|
|
|
||
| ● |
new product and services development and commercialization; |
|
|
|
||
| ● |
key strategic alliances with vendors and channel partners that resell our products; |
|
|
|
||
| ● |
uncertainty in continued relationships with customers due to termination rights; |
|
|
|
||
| ● |
our ability to control costs; |
|
|
|
||
| ● |
availability, quality and security of products produced, and services provided by third-party vendors; |
|
|
|
||
| ● |
the healthcare regulatory environment; |
|
|
|
||
| ● |
potential changes in legislation, regulation and government funding affecting the healthcare industry; |
|
|
|
||
| ● |
healthcare information systems budgets; |
| ● |
availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems; |
|
|
|
||
| ● |
the success of our relationships with channel partners; |
|
|
|
||
| ● |
fluctuations in operating results; |
|
|
|
||
| ● |
our future cash needs; |
|
|
|
||
| ● |
the consummation of resources in researching acquisitions, business opportunities or financings and capital market transactions; |
|
|
|
||
| ● |
the failure to adequately integrate past and future acquisitions into our business; |
|
|
|
||
| ● |
critical accounting policies and judgments; |
|
|
|
||
| ● |
changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other standard-setting organizations; |
|
|
|
||
| ● |
changes in economic, business and market conditions impacting the healthcare industry and the markets in which we operate; |
|
|
|
||
| ● |
impairment of our goodwill and other intangible assets; |
|
|
|
||
| ● |
the extent to which health epidemics and other outbreaks of communicable diseases could disrupt our operations and/or materially and adversely affect our business and financial conditions; |
|
|
|
||
| ● |
our ability to maintain compliance with the terms of our credit facilities; and |
|
|
|
||
| ● |
our ability to maintain compliance with the continued listing standards of the Nasdaq Capital Market (“Nasdaq”). |
Most of these risk factors are beyond our ability to predict or control. Any of these factors, or a combination of these factors, could materially affect our future financial condition or results of operations and the ultimate accuracy of our forward-looking statements. There also are other factors that we may not describe (generally because we currently do not perceive them to be material) that could cause actual results to differ materially from our expectations. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Overview
On August 16, 2021, the Company entered into a Unit Purchase Agreement (“UPA”) to acquire Avelead, a recognized leader in providing solutions and services to improve revenue integrity for healthcare providers nationwide. The Company believes Avelead’s solutions will complement and extend the value the Company can deliver to its customers. Operations for Avelead are included in the Company’s consolidated financial information from the acquisition date. Refer to Note 3 – Business Combination in our unaudited condensed consolidated financial statements included in Part I, Item I, “Financial Statements” for further information on the Avelead acquisition.
On October 16, 2023, the Company announced it was executing a Strategic Restructuring designed to reduce expenses while maintaining the Company’s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting in the termination of 26 employees, or approximately 24% of the Company’s workforce. To execute the Strategic Restructuring, the Company recorded $759,000 of expenses in the three months ending January 31, 2024, which consisted of approximately $731,000 in severance and other employee termination-related expenses and approximately $28,000 in incurred legal fees. As of April 30, 2024, the Company has recorded all expenses related to the Strategic Restructuring with $9,000 of severance payouts payable. The Company expects to realize approximately $5,800,000 in annualized cost savings as a result of the Strategic Restructuring.
Results of Operations
Revenues
| Three Months Ended |
||||||||||||||||
| ($ in thousands): |
April 30, 2024 |
April 30, 2023 |
Change |
% Change |
||||||||||||
| Software as a service |
$ | 2,723 | $ | 3,175 | $ | (452 | ) | (14 | )% | |||||||
| Maintenance and support |
$ | 890 | 1,157 | (267 | ) | (23 | )% | |||||||||
| Professional fees and licenses |
$ | 717 | 1,000 | (283 | ) | (28 | )% | |||||||||
| Total Revenues |
$ | 4,330 | $ | 5,332 | $ | (1,002 | ) | (19 | )% | |||||||
Software as a Service (SaaS) — Revenue from SaaS for the three months ended April 30, 2024 decreased by $452,000 compared to the same period in the prior year. A previously announced client non-renewal contributed to a decrease of $944,000 for the three months ended April 30, 2024, compared to the corresponding three-month period ended April 30, 2023. New clients on the Company’s eValuator and RevID products provided an offset to the negative impact of the client non-renewal. The Company expects sequential growth in each quarter of fiscal 2024 as the Company replenishes the lost revenue related to the non-renewal of the client contract.
The Company had approximately $3.9 million of annualized contract value of SaaS contracts to be implemented as of April 30, 2024. The Company is seeing improvements in the contract-to-implementation timelines compared to the prior year. The industry had been impacted by hospital personnel shortages and a backlog of hospital IT projects. Despite this positive trend, the Company remains uncertain how long the broader industry challenges will continue to affect our implementation schedules.
Maintenance and support — For the three months ended April 30, 2024, revenue from maintenance and support decreased by $267,000 compared to the same period in the prior year. As the Company continues to prioritize SaaS products, we anticipate the maintenance and support revenue will decline in fiscal 2024 attributed to expected contract non-renewals, and limited new sales.
Professional fees and licenses — Revenues from professional fees and licenses include proprietary software, term license, professional services and audit and coding services revenue. Total professional fees and license revenues for the three months ended April 30, 2024, decreased by $283,000 compared to the same period in the prior year. The Company has primarily shifted the business from perpetual software licenses to a SaaS model. Software license sales come solely from our channel partners; therefore, the periodic amounts are less predictable and consistent than recurring revenues.
For the three months ended April 30, 2024, revenue from professional services decreased by $153,000 compared to the same period in the prior year. Professional services for a subset of the Company's solutions, are recognized as the services are performed. The Company expects professional services revenue to fluctuate based on the timing and combination of products currently being implemented. The Company saw an increase in license revenue of $61,000 in the first fiscal quarter of 2024 compared to the same period in the prior year. The Company is primarily focused on growth of its SaaS products, and, accordingly, is not expecting growth in license revenue for the remainder of the fiscal year.
For the three-month period ended April 30, 2024, revenue from audit services decreased by $190,000 compared to the prior year period. The decrease was driven primarily by three client terminations. Certain existing clients shifted their demand for audit services which resulted in an increase of audit services revenue of $22,000 for the three-month period ending April 30, 2024, compared to the prior year period. The Company believes demand for its onshore, technically proficient coders and auditors in the marketplace is strong and that it has a competitive edge in providing audit and coding services as an offering with the eValuator solution as a technology-enabled service. To support the shifting demand among clients, the Company anticipates the audit and coding services to remain relatively flat throughout fiscal year 2024.
Cost of Sales
| Three Months Ended |
||||||||||||||||
| (in thousands): |
April 30, 2024 |
April 30, 2023 |
Change |
% Change |
||||||||||||
| Cost of software as a service |
$ | 1,348 | $ | 1,589 | $ | (241 | ) | (15 | )% | |||||||
| Cost of maintenance and support |
42 | 89 | (47 | ) | (53 | )% | ||||||||||
| Cost of professional fees and licenses |
887 | 1,108 | (221 | ) | (20 | )% | ||||||||||
| Total cost of sales |
$ | 2,277 | $ | 2,786 | $ | (509 | ) | (18 | )% | |||||||
Cost of software as a service (SaaS) – The cost of SaaS consists of expenses associated with (i) amortization of capitalized software, (ii) royalties payable to third-parties for use of their coding related content, and (iii) personnel and network infrastructure required to deploy and support applications for each client. For the three months ended April 30, 2024, the cost of SaaS solutions decreased $241,000 compared to the prior year period. The decrease is driven by lower infrastructure costs of $124,000 and lower contract and personnel costs of $180,000 offset by an increase in third-party related royalties of $63,000, and amortization of capitalized software remained relatively unchanged. Certain expenses included in our cost of SaaS are tied to volumes. These expenses include coding tools supporting eValuator and a third-party system that translates data from the hospital system to the Company’s systems. The Company expects these costs of SaaS solutions to increase as revenue increases.
For the three months ended April 30, 2024, and 2023, the cost of SaaS solutions includes non-cash charges of $545,000 and $554,000, respectively, related to the amortization of capitalized software. The Company expects margins related to SaaS solutions to increase in the future for clients currently in the process of implementation. Certain costs included in cost of SaaS, such as labor and third-party content providers, negatively impact gross margin before a client is fully implemented and revenue is recognized.
Cost of maintenance and support – The cost of maintenance and support includes compensation and benefits for client support personnel required to provide product support for clients on our CDI and Abstracting software licenses. This cost decreased by $47,000 for the three months ended April 30, 2024, compared to the prior year period.
Cost of professional fees and licenses – The cost of professional fees and licenses includes the cost of software licenses, the cost of professional services and the cost of audit and coding services. The aggregate cost of professional fees and licenses decreased for the three months ended April 30, 2024, by $221,000 compared to the prior year period.
The cost of professional fees includes compensation and benefits for personnel and related expenses. For the three months ended April 30, 2024, professional services costs decreased by approximately $69,000 compared to the prior year period. This decrease was driven by a reduction in staff resulting in lower personnel and third-party contractor costs. The costs of professional fees are expected to remain relatively flat throughout fiscal year 2024.
The cost of audit services includes compensation and benefits for internal audit services personnel, and related expenses. The costs for the three months ended April 30, 2024, decreased by approximately $162,000 compared to the prior year period. The reduction of personnel and related expenses is a response to matching the shifting demand for the Company's audit services.
The cost of software licenses for the three months ended April 30, 2024 increased by $10,000 compared to the same prior year period due to the amortization of development costs related to the Company’s coding/CDI product. The Company expects the remaining capitalized Coding and CDI software license costs to be fully amortized by the end of fiscal 2024.
Selling, General and Administrative Expense
| Three Months Ended |
||||||||||||||||
| ($ in thousands): |
April 30, 2024 |
April 30, 2023 |
Change |
% Change |
||||||||||||
| General and administrative expenses |
$ | 2,246 | $ | 2,619 | $ | (373 | ) | (14 | )% | |||||||
| Sales and marketing expenses |
946 | 1,222 | (276 | ) | (23 | )% | ||||||||||
| Total selling, general, and administrative expense |
$ | 3,192 | $ | 3,841 | $ | (649 | ) | (17 | )% | |||||||
General and administrative expenses comprise various costs including compensation and associated benefits, reimbursable travel and entertainment expenses related to our executive and administrative staff, general corporate expenditures, amortization of intangible assets, and occupancy costs. For the three months ended April 30, 2024, the decrease in general and administrative expenses of $373,000 was driven primarily by a decrease in compensation and related benefits of $412,000. The Company saw an increase in director fees and audit financial fees, offset by office rent and amortization in the three months ended April 30, 2024, compared to the prior year period. Overall, despite some increases in specific areas, the Company is successfully implementing cost saving initiatives to its general and administrative expenses for the three months ended April 30, 2024.
Sales and marketing expenses primarily encompass compensation, associated benefits, travel and entertainment costs for our sales and marketing personnel. Additionally, sales and marketing expenses include costs from third parties related to advertising, marketing and trade show attendance. For the three months ended April 30, 2024, sales and marketing expenses decreased by $276,000 compared to the prior year period.
Research and Development
| Three Months Ended |
||||||||||||||||
| ($ in thousands): |
April 30, 2024 |
April 30, 2023 |
Change |
% Change |
||||||||||||
| Research and development expenses |
$ | 1,111 | $ | 1,701 | $ | (590 | ) | (35 | )% | |||||||
| Capitalized research and development cost |
247 | 404 | (157 | ) | (39 | )% | ||||||||||
Research and development expenses consist primarily of compensation and related benefits and the use of independent contractors for specific near-term development projects. Research and development expenses for the three months ended April 30, 2024, decreased by $590,000 compared to the prior year period. The three months ended April 30, 2023, included additional outside staff augmentation and higher headcount related expenses. The Company continues to focus research and development activities on eValuator and RevID, its flagship SaaS solutions.
Capitalized research and development costs for the three months ended April 30, 2024, decreased by $157,000 compared to the prior year period.
Other Income (Expense)
| Three Months Ended |
||||||||||||||||
| ($ in thousands): |
April 30, 2024 |
April 30, 2023 |
Change |
% Change |
||||||||||||
| Interest expense |
$ | (465 | ) | $ | (248 | ) | $ | (217 | ) | 88 | % | |||||
| Valuation adjustments |
(24 | ) | 364 | (388 | ) | (107 | )% | |||||||||
| Miscellaneous income (expense) |
— | 32 | (32 | ) | (100 | )% | ||||||||||
| Total other income |
$ | (489 | ) | $ | 148 | $ | (637 | ) | (430 | )% | ||||||
Interest expense consists of interest associated with the term loan, notes payable, and their respective deferred financing costs, less interest related to capitalization of software. For the three months ended April 30, 2024, interest expense increased by $217,000 compared to the prior year period. The increase was primarily attributable to $4,400,000 of notes payable (See Note 5 – Debt).
Valuation adjustments are related to the liabilities associated with the Avelead acquisition (Refer to Note 3 – Business Combination of the unaudited condensed consolidated financial statements included in Part I, Item I, “Financial Statements”), and the common stock underlying the Warrants (Refer to Note 5 – Debt). For the three months ended April 30, 2024 and 2023, the Company recorded valuation adjustments of $24,000 and $364,000, respectively. The valuation adjustments are caused by the decrease in the value of the stock to be transferred and that decreases affect on the Black Scholes model used for valuing the Warrants.
There was no miscellaneous income or expense for the period ended April 30, 2024. Miscellaneous income for the three months ended April 30, 2023, is primarily from the sublease of the Alpharetta location (Refer to Note 4 – Operating Leases of the unaudited condensed consolidated financial statements included in Part I, Item I, “Financial Statements”).
Provision for Income Taxes
We recorded an income tax benefit of $0 and income tax expense of $53,000 for the three months ended April 30, 2024 and 2023, respectively, which is comprised of estimated federal, state and local income tax provisions. The Company has a substantial amount of net operating losses for federal and state income tax purposes. The effective income tax rate on continuing operations of approximately 0% differs from our combined federal and state statutory rate of 24% primarily due to the full valuation allowance the Company currently maintains on its net deferred tax asset.
Use of Non-GAAP Financial Measures
In order to provide investors with greater insight and allow for a more comprehensive understanding of the information used by management and the Board of Directors in its financial and operational decision-making, the Company has supplemented the condensed consolidated financial statements presented on a GAAP basis in this Report with the following non-GAAP financial measures: EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin.
These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of Company results as reported under GAAP. The Company compensates for such limitations by relying primarily on our GAAP results and using non-GAAP financial measures only as supplemental data. We also provide a reconciliation of non-GAAP to GAAP measures used. Investors are encouraged to carefully review this reconciliation. In addition, because these non-GAAP measures are not measures of financial performance under GAAP and are susceptible to varying calculations, these measures, as defined by us, may differ from and may not be comparable to similarly titled measures used by other companies.
EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin
We define: (i) EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; (ii) Adjusted EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation, amortization, share-based compensation expense, transaction related expenses and other expenses that do not relate to our core operations such as severances and impairment charges; and (iii) Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of GAAP net revenue. EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are used to facilitate a comparison of our operating performance on a consistent basis from period to period and provide for a supplemental understanding of factors and trends affecting our business than GAAP measures alone. These measures assist management and the Board of Directors, and may be useful to investors in comparing our operating performance consistently over time as they remove the impact of our capital structure (primarily interest charges), asset base (primarily depreciation and amortization), items outside the control of the management team (taxes) and expenses that do not relate to our core operations including: transaction-related expenses (such as professional and advisory services), corporate restructuring expenses (such as severances) and other operating costs that are expected to be non-recurring. Adjusted EBITDA removes the impact of share-based compensation expense, which is another non-cash item.
The Board of Directors and management also use these measures (i) as one of the primary methods for planning and forecasting overall expectations and for evaluating, on at least a quarterly and annual basis, actual results against such expectations; and (ii) as a performance evaluation metric in determining achievement of certain executive and associate incentive compensation programs.
Our lender uses a measurement that is similar to the Adjusted EBITDA measurement described herein to assess our operating performance. The lender under our Second Amended and Restated Loan Agreement requires delivery of compliance reports certifying compliance with financial covenants, certain of which are based on a measurement that is similar to the Adjusted EBITDA measurement reviewed by our management and Board of Directors.
EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin are not measures of liquidity under GAAP or otherwise and are not alternatives to cash flow from continuing operating activities, despite the supplemental information provided by these measures regarding the use and analysis of these measures as mentioned above. EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin, as disclosed in this Report have limitations as analytical tools, and you should not consider these measures in isolation or as a substitute for analysis of our results as reported under GAAP; nor are these measures intended to be measures of liquidity or free cash flow for our discretionary use. Some of the limitations of EBITDA and its variations are:
| ● |
EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; |
|
|
|
||
| ● |
EBITDA does not reflect changes in, or cash requirements for, our working capital needs; |
|
|
|
||
| ● |
EBITDA does not reflect the interest expense, or the cash requirements to service interest or principal payments under our Second Amended and Restated Loan Agreement; |
|
|
|
||
| ● |
EBITDA does not reflect income tax payments that we may be required to make; and |
|
|
|
||
| ● |
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements. |
Adjusted EBITDA has all the inherent limitations of EBITDA. To properly and prudently evaluate our business, the Company encourages readers to review the GAAP financial statements included elsewhere in this Report, and not rely on any single financial measure to evaluate our business. We also strongly urge readers to review the reconciliation of these non-GAAP financial measures to the most comparable GAAP measure in this section, along with the condensed consolidated financial statements included above.
The following table reconciles EBITDA and Adjusted EBITDA to net loss for the three months ended April 30, 2024 and 2023 (amounts in thousands). All of the items included in the reconciliation from EBITDA and Adjusted EBITDA to net loss are either recurring non-cash items, or items that management does not consider in assessing our on-going operating performance. In the case of the non-cash items, management believes that investors may find it useful to assess the Company’s comparative operating performance because the measures without such items are less susceptible to variances in actual performance resulting from depreciation, amortization and other expenses that do not relate to our core operations and are more reflective of other factors that affect operating performance. In the case of items that do not relate to our core operations, management believes that investors may find it useful to assess our operating performance if the measures are presented without these items because their financial impact does not reflect ongoing operating performance.
| Three Months Ended |
||||||||
| In thousands, except per share data |
April 30, 2024 |
April 30, 2023 |
||||||
| Adjusted EBITDA Reconciliation |
||||||||
| Net Loss |
$ | (2,739 | ) | $ | (2,901 | ) | ||
| Interest expense |
465 | 248 | ||||||
| Income tax expense |
— | 53 | ||||||
| Depreciation and amortization |
1,017 | 1,031 | ||||||
| EBITDA |
$ | (1,257 | ) | $ | (1,569 | ) | ||
| Share-based compensation expense |
499 | 572 | ||||||
| Non-cash valuation adjustments |
24 | (364 | ) | |||||
| Acquisition-related costs, severance, and transaction-related bonuses |
31 | 57 | ||||||
| Other non-recurring charges |
— | (33 | ) | |||||
| Adjusted EBITDA |
$ | (703 | ) | $ | (1,337 | ) | ||
| Adjusted EBITDA margin (1) |
(16 | )% | (25 | )% | ||||
| (1) |
Adjusted EBITDA as a percentage of GAAP net revenue. |
Application of Critical Accounting Policies
The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Management considers an accounting policy to be critical if the accounting policy requires management to make particularly difficult, subjective, or complex judgments about matters that are inherently uncertain. A summary of our critical accounting policies is included in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024. Except as discussed below, there have been no material changes to the critical accounting policies disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024.
Liquidity, Capital Resources, and Going Concern
The Company’s liquidity is dependent upon numerous factors including: (i) the timing and amount of revenue and collection of contractual amounts from customers, (ii) amounts invested in research and development and capital expenditures, and (iii) the level of operating expenses, all of which can vary significantly from quarter to quarter. The Company’s primary cash requirements include regular payment of payroll and other business expenses, principal and interest payments on debt and capital expenditures, which generally include computer hardware. Operations are funded with cash generated by operations and borrowings under credit facilities. Information concerning the Company’s assessment as a going concern is included in Note 1 – Basis of Presentation in our unaudited condensed consolidated financial statements included in Part I, Item I, “Financial Statements”. Cash and cash equivalent balances at April 30, 2024 and January 31, 2024, were approximately $3,979,000 and $3,190,000, respectively. We expect that our cash flow from operations, current cash and cash equivalents and available borrowing capacity under the Second Amended and Restated Loan Agreement (as defined below) will be sufficient to meet our present and future working capital and cash requirements for at least the next twelve months.
The Company has liquidity through its Second Amended and Restated Loan Agreement (as amended and modified, the "Second Amended and Restated Loan Agreement") described in more detail in Note 5 – Debt in our unaudited condensed consolidated financial statements included in Part I, Item I, “Financial Statements." Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial, maximum, principal amount of $10,000,000. Amounts outstanding under the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Company executed a Second Modification to Second Amended and Restated Loan Agreement (the “Second Modification”) on November 29, 2022, which amended the covenants under the Second Amended and Restated Loan Agreement expanded the Company’s total borrowing to include a $2,000,000 non-formula revolving line of credit. The revolving line of credit will be co-terminus with the term loan and matures on August 26, 2026. The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 and April 5, 2024, respectively (collectively, the “Third and Fourth Modifications”). The Third and Fourth Modifications reestablished certain customary financial covenants for the Second Amended and Restated Loan Agreement. Refer to Note 5 – Debt for information regarding the Second Amended and Restated Loan Agreement, Second Modification and Third and Fourth Modifications.
The Second Amended and Restated Loan Agreement includes customary financial covenants, including the requirements that the Company achieve certain EBITDA levels and ratios, ARR net leverage ratios, and fixed charge coverage ratios. The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default. As of April 30, 2024, the Company was in compliance with all debt covenants under the Second Amended and Restated Loan Agreement.
Significant cash obligations
| (in thousands) |
April 30, 2024 |
January 31, 2024 |
||||||
| Term loan (1) |
$ | 8,839 | $ | 9,066 | ||||
| Notes payable (2) |
3,587 | — | ||||||
| Acquisition earnout liability (3) |
817 | 1,794 | ||||||
| Warrants – common stock (4) |
746 | — | ||||||
| Line of credit (5) |
— | 1,500 | ||||||
| (1) |
Term loan balance is reported net of deferred financing costs of $61,000 and $69,000 as of April 30, 2024 and January 31, 2024, respectively, and financing cost payable of $150,000 and $135,000 as of April 30, 2024 and January 31, 2024, respectively. Refer to Note 5 – Debt for additional information. The term loan payable as of April 30, 2024 and January 31, 2024 was bank term debt under the Second Amended and Restated Loan Agreement. |
|
|
|
| (2) |
Refer to Note 5 – Debt for additional information. The cash obligation is net of discounts on notes payable of $796,000 and deferred financing costs of $169,000. |
|
|
|
| (3) |
The fair value of the acquisition earnout liability is based upon a probability-weighted discounted cash flow as of January 31, 2024. As of April 30, 2024, the acquisition earnout liability reflects the cash balance which is expected to be paid out by October 31, 2024. Refer to Note 3 – Business Combination for additional information. |
|
|
|
| (4) | Refer to Note 5 – Debt for additional information. The warrants include a registration rights provision that provides the individual holders with certain "net cash settlement" rights at their discretion. The Company is only obligated for this cash amount if the warrant holders are able and elect to request the "net cash settlement." |
|
|
|
| (5) |
Refer to Note 5 – Debt for additional information. The outstanding balance on the line of credit was paid in full as of April 30, 2024. |
Operating cash flow activities
| Three Months Ended |
||||||||
| (in thousands) |
April 30, 2024 |
April 30, 2023 |
||||||
| Net loss |
$ | (2,739 | ) | $ | (2,901 | ) | ||
| Non-cash adjustments to net loss |
1,795 | 1,306 | ||||||
| Cash impact of changes in assets and liabilities |
(255 | ) | 1,721 | |||||
| Net cash (used in) provided by operating activities |
$ | (1,199 | ) | $ | 126 | |||
The net cash used in operating activities increased during the three months ended April 30, 2024, compared to the prior year comparable period. The Company observed a slightly slower conversion of accounts receivable for the period ended April 30, 2024, that contributed to the increase in cash used in operating activities.
Investing cash flow activities
| Three Months Ended |
||||||||
| (in thousands) |
April 30, 2024 |
April 30, 2023 |
||||||
| Purchases of property and equipment |
$ | — | $ | (29 | ) | |||
| Capitalized software development costs |
(232 | ) | (404 | ) | ||||
| Net cash (used in) provided by investing activities |
$ | (232 | ) | $ | (433 | ) | ||
The cash used in investing activities for the three months ended April 30, 2024 and April 30, 2023, includes capitalized software development costs. The Company expects continued capitalizable projects associated with the Company’s flagship products; however, the rate of capitalization may temporarily remain constant or decrease as a result of the Strategic Restructuring announced in October 2023.
Financing cash flow activities
| Three Months Ended |
||||||||
| (in thousands) |
April 30, 2024 |
April 30, 2023 |
||||||
| Proceeds from notes payable |
$ | 4,400 | $ | (125 | ) | |||
| Proceeds from issuance of common stock |
100 | — | ||||||
| Payments for deferred financing costs |
(16 | ) | — | |||||
| Payments related to settlement of employee share-based awards |
(67 | ) | — | |||||
| Repayment of term loan payable |
(250 | ) | — | |||||
| Payments of acquisition earnout liabilities |
(447 | ) | — | |||||
| Repayment of line of credit |
(1,500 | ) | (179 | ) | ||||
| Net cash (used in) provided by financing activities |
$ | 2,220 | $ | (304 | ) | |||
The cash used in financing activities for the three months ended April 30, 2024, and April 30, 2023, includes principal payments on the term loan related to the Second Amended and Restated Loan Agreement, repayment on the line of credit, and payments related to settlement of employee share-based awards. The cash provided by financing activities for the three months ended April 30, 2024, includes proceeds received in connection with the issuance of the Notes in the Debt Private Placement, which closed in February 2024.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a “smaller reporting company,” as defined by Item 10 of Regulation S-K, we are not required to provide this information.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our President and Chief Executive Officer (who serves as our principal executive officer) and our Chief Financial Officer (who serves as our principal financial officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(c)) as of April 30, 2024. Based on that evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of April 30, 2024, due to the material weakness described below.
Material Weakness in Internal Control Over Financial Reporting
The Company identified a material weakness in our internal control over financial reporting related to our accounting and classification for the warrants issued in connection with the debt private placement in February 2024. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our internal control over financial reporting did not detect the proper accounting classification of the warrants issued in connection with the private placement. The change in the classification impacted initial allocation of proceeds for the transaction, the presentation and recognition of the warrants between equity and liability and the recognition of expenses allocated to the warrants originated. As a result of this material weakness, our management concluded that our internal control over financial reporting was not effective as of April 30, 2024.
Remediation of Material Weakness in Internal Control Over Financial Reporting
To respond to this material weakness, management is working to remediate the material weakness and enhance our overall control environment. Our remediation plan includes expanding and improving our review process, particularly in the context of complex financial instruments and related accounting standards, as well as internal communications in connection therewith. In addition, management will continue to engage third-party professionals with whom to consult regarding complex accounting applications. The Company will consider the material weakness remediated after the applicable controls operate for a sufficient period of time and are tested. We can provide no assurance that our remediation efforts described herein will be successful and that we will not have material weaknesses in the future.
Changes in Internal Control over Financial Reporting
Except for the material weakness described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended April 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 1. LEGAL PROCEEDINGS
We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware of any legal matters that could have a material adverse effect on our consolidated results of operations, financial position, or cash flows.
An investment in our common stock or other securities involves a number of risks. You should carefully consider each of the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 which Annual Report includes a detailed discussion of the Company’s risk factors. If any of the risks develop into actual events, our business, financial condition, or results of operations could be negatively affected, the market price of our common stock or other securities could decline, and you may lose all or part of your investment.
Except as described below, there have been no material changes to the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 31, 2024.
If we do not meet the continued listing standards of The Nasdaq Capital Market, our common stock could be delisted from trading, which could limit investors’ ability to make transactions in our common stock and subject us to additional trading restrictions.
Our common stock is currently listed on The Nasdaq Capital Market which imposes continued listing requirements with respect to listed shares. On October 24, 2023, we received a letter from the Listing Qualifications Department (the “Staff”) of Nasdaq, indicating that our common stock was subject to potential delisting from The Nasdaq Capital Market because, for a period of thirty (30) consecutive business days, the bid price of our common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). Nasdaq stated in its letter that in accordance with the Nasdaq Listing Rules, we have been provided an initial period of one hundred eighty (180) calendar days, or until April 22, 2024, to regain compliance with the Bid Price Requirement. The letter states that Nasdaq will provide written notification that we have achieved compliance with the Bid Price Requirement if at any time before April 22, 2024, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 calendar days, or until April 22, 2024, to regain compliance with the Minimum Bid Price Requirement.
On April 23, 2024, the Company received a letter from the Staff informing the Company that, while the Company has not regained compliance with the Bid Price Requirement, the Staff has determined that the Company is eligible for an additional 180 calendar day period, or until October 21, 2024 (the “Second Compliance Period”), to regain compliance. If at any time during the Second Compliance Period, the closing bid price of our common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide the Company with written confirmation of compliance. If compliance with the Bid Price Requirement cannot be demonstrated by October 21, 2024, the Staff will provide written notification that our common stock will be delisted. At that time, the Company may appeal the Staff’s determination to a Hearings Panel.
In the event that our common stock is delisted from The Nasdaq Capital Market and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange.
Such a delisting would also likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we may take actions to restore our compliance with The Nasdaq Capital Market listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Bid Price Requirement or prevent future non-compliance with The Nasdaq Capital Market listing requirements.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Avelead Earnout
On March 27, 2024, the Company issued 961,640 shares of restricted common stock, par value $0.01 per share (the “restricted common stock”) to the Sellers for the SaaS Contingent Consideration (as defined in the UPA) and 627,746 shares of restricted common stock for the Renewal Contingent Consideration (as defined in the UPA). These liabilities are reflected at the fair value of the future commitment on the Company’s consolidated balance sheet as “acquisition earnout liability.” The Company and the Sellers reached an agreement to defer the cash portion of the SaaS Contingent Consideration and Renewal Contingent Consideration payments over time through October 31, 2024.
Share Repurchases
The following table sets forth information with respect to our repurchases of common stock during the three months ended April 30, 2024:
| Total |
Maximum |
|||||||||||||||
| Number of |
Number of |
|||||||||||||||
| Shares |
Shares |
|||||||||||||||
| Purchased |
that May |
|||||||||||||||
| Total |
as Part of |
Yet Be |
||||||||||||||
| Number of |
Publicly |
Purchased |
||||||||||||||
| Shares |
Average |
Announced |
under the |
|||||||||||||
| Purchased |
Price Paid |
Plans or |
Plans or |
|||||||||||||
| (1) |
per Share |
Programs |
Programs |
|||||||||||||
| February 1 - February 29 |
10,821 | $ | 0.51 | — | — | |||||||||||
| March 1 - March 31 |
39,882 | 0.49 | — | — | ||||||||||||
| April 1 - April 30 |
88,402 | 0.48 | — | — | ||||||||||||
| Total |
139,105 | $ | 0.49 | — | — | |||||||||||
February 2024 Private Placements
In February 2024, the Company closed private placements of common stock, unsecured promissory notes and warrants resulting in aggregate gross proceeds of approximately $4,500,000. Refer to Note 5 – Debt and Note 7 – Equity for additional information related to the private placements.
The offer, sale and issuance of the securities described above were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with the view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the certificates (or book entries representing such securities) issued in these transactions.
Item 5. OTHER INFORMATION
During the three months ended April 30, 2024, of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).
See Index to Exhibits.
INDEX TO EXHIBITS
| * |
Filed herewith. |
Our SEC file number reference for documents filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended, is 000-28132.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| STREAMLINE HEALTH SOLUTIONS, INC. |
||
| DATE: June 12, 2024 |
By: |
/s/ Benjamin L. Stilwill |
| Benjamin L. Stilwill President and Chief Executive Officer |
||
| DATE: June 12, 2024 |
By: |
/s/ Bryant J. Reeves III |
| Bryant J. Reeves III |
||
| Chief Financial Officer |
||
Exhibit 10.4
FOURTH MODIFICATION
TO
SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
THIS FOURTH MODIFICATION TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Modification”) is entered into as of April 5, 2024 by and among STREAMLINE HEALTH SOLUTIONS, INC., a Delaware corporation (“Streamline”), STREAMLINE HEALTH, LLC, a Delaware limited liability company (f/k/a STREAMLINE HEALTH, INC., an Ohio corporation) (“Streamline Health”), STREAMLINE PAY & BENEFITS, LLC, a Delaware limited liability company (“Streamline Pay”), AVELEAD CONSULTING, LLC, a Georgia limited liability company (“Avelead Consulting”), STREAMLINE CONSULTING SOLUTIONS, LLC, a Delaware limited liability company (“Streamline Consulting” and, together with Streamline, Streamline Health, Streamline Pay, Avelead Consulting and any other Person who, from time to time, becomes a Borrower under the Loan Agreement (as defined below), collectively, the “Borrowers” and each individually, a “Borrower”) and WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”).
RECITALS
A. Bank and Borrower have previously entered into that certain Second Amended and Restated Loan and Security Agreement dated as of August 26, 2021 (as amended, restated, supplemented and otherwise modified from time to time, the “Loan Agreement”), pursuant to which Bank has made certain loans and financial accommodations available to Borrower.
B. Bank and Borrower now wish to modify the Loan Agreement on the terms and conditions set forth herein.
C. Borrower is entering into this Modification with the understanding and agreement that, except as specifically provided herein, none of Bank’s rights or remedies as set forth in the Loan Agreement or any other Loan Document is being waived or modified by the terms of this Modification.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. MODIFICATIONS.
(a) Maximum Debt to Adjusted EBITDA Ratio. Section 6.9(c) of the Loan Agreement is hereby deleted in its entirety and the following substituted therefor:
“(c) Maximum Debt to Adjusted EBITDA Ratio. Commencing with the quarter ending April 30, 2025, Borrowers’ Maximum Debt to Adjusted EBITDA Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended, shall not be greater than the amount set forth under the heading “Maximum Debt to Adjusted EBITDA Ratio” as of, and for each of the dates appearing adjacent to such “Maximum Debt to Adjusted EBITDA Ratio”.
|
Quarter Ending |
Maximum Debt to Adjusted EBITDA Ratio |
|
April 30, 2025 |
3.50 to 1.00 |
|
July 31, 2025 |
3.00 to 1.00 |
|
October 31, 2025 |
2.50 to 1.00 |
|
January 31, 2026 and on the last day of each quarter thereafter |
2.00 to 1.00 |
(b) Compliance Certificate. Exhibit B to the Loan Agreement is hereby deleted in its entirety and replaced with Exhibit B attached hereto.
2. NO DEFENSES OF BORROWER/GENERAL RELEASE. Each Borrower agrees that, as of this date, it has no defenses against the obligations to pay any amounts under the Indebtedness. Each Borrower acknowledges that Bank would not enter into this Modification without Borrower’s assurance that it has no claims against Bank or any of Bank’s officers, directors, employees or agents. Except for any claims or obligations arising after the date of this Modification, each Borrower releases Bank, and each of Bank’s officers, directors and employees from any known or unknown claims that such Borrower now has against Bank of any nature, including any claims that such Borrower, its successors, counsel, and advisors may in the future discover they would have now had if they had known facts not now known to them, whether founded in contract, in tort or pursuant to any other theory of liability, including but not limited to any claims arising out of or related to the Loan Agreement or the transactions contemplated thereby. Each Borrower acknowledges and agrees that they have been informed by their attorneys and advisors of, and are familiar with, and do hereby expressly waive, the provisions of Section 1542 of the California Civil Code, and any similar statute, code, law, or regulation of any state or the United States, to the full extent that they may waive such rights and benefits. Civil Code section 1542 provides:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR A BORROWER DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
The provisions, waivers and releases set forth in this section are binding upon each Borrower and its shareholders, agents, employees, assigns and successors in interest. The provisions, waivers and releases of this section shall inure to the benefit of Bank and its agents, employees, officers, directors, assigns and successors in interest. The provisions of this section shall survive payment in full of the Obligations, full performance of all the terms of this Modification and the Loan Agreement, and/or Bank’s actions to exercise any remedy available under the Loan Agreement or otherwise.
3. CONTINUING VALIDITY. Borrowers understand and agree that in modifying the existing Indebtedness, Bank is relying upon Borrowers’ representations and warranties set forth in this Modification and the reaffirmation of Borrowers’ performance obligations under the Loan Documents, subject to the modifications set forth herein. Except as expressly modified pursuant to this Modification, the terms of the Loan Documents remain unchanged and in full force and effect. Bank’s agreement to modifications to the existing Indebtedness pursuant to this Modification in no way shall obligate Bank to make any future modifications to the Indebtedness. Nothing in this Modification shall constitute a satisfaction of the Indebtedness. It is the intention of Bank and Borrowers to retain as liable parties all makers and endorsers of Loan Documents, unless the party is expressly released by Bank in writing. No maker, endorser, or guarantor will be released by virtue of this Modification. The terms of this paragraph apply not only to this Modification, but also to any subsequent modification agreements.
4. EFFECTIVENESS OF THIS MODIFICATION. This Modification, and the waivers provided for herein, shall become effective upon the satisfaction, as determined by Bank, of the following conditions.
(a) Modification. Bank shall have received this Modification fully executed in a sufficient number of counterparts for distribution to all parties.
(b) Representations and Warranties. The representations and warranties set forth herein and in the Loan Agreement are true and correct in all material respects (except for such representations and warranties qualified by materiality, which shall be true and correct in all respects).
(c) Other Required Documentation. All other documents and legal matters in connection with the transactions contemplated by this Modification shall have been delivered or executed or recorded, as required by Bank.
Bank shall provide prompt written notice (e-mail to suffice) to Borrowers confirming the satisfaction of the conditions in this Section 6 and the effectiveness of this Modification, which confirmation shall be binding on Bank.
5. CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER; REFERENCE PROVISION. This Modification constitutes a “Loan Document” as defined and set forth in the Loan Agreement, and is subject to Sections 11 and 12 of the Loan Agreement, which are incorporated by reference herein.
6. NOTICE OF FINAL AGREEMENT. By signing this document each party represents and agrees that: (A) this written agreement represents the final agreement between the parties, (B) there are no unwritten oral agreements between the parties, and (C) this written agreement may not be contradicted by evidence of any prior, contemporaneous, or subsequent oral agreements or understandings of the parties.
7. COUNTERPARTS; FACSIMILE SIGNATURES. This Modification may be executed in any number of and by different parties hereto on separate counterparts, all of which, when so executed, shall be deemed an original, but all such counterparts shall constitute one and the same agreement. Any signature delivered by a party by facsimile or other similar form of electronic transmission shall be deemed to be an original signature hereto.
8. RATIFICATION. Borrowers hereby covenant and agree to comply with each and every term and condition set forth in the Loan Agreement, as amended hereby, and the other Loan Documents effective as of the date hereof, and hereby reaffirm their various obligations thereunder.
9. INTEGRATION. This Modification, together with the Loan Agreement and the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.
[Signature Page Follows]
| BORROWER: | ||
| STREAMLINE HEALTH SOLUTIONS, INC. | ||
| By: /s/ Bryant J. Reeves, III | ||
| Name: Bryant J. Reeves, III | ||
| Title: Interim Chief Financial Officer | ||
| STREAMLINE HEALTH, LLC (F/K/A STREAMLINE HEALTH, INC.) | ||
| By: /s/ Bryant J. Reeves, III | ||
| Name: Bryant J. Reeves, III | ||
| Title: Authorized Signatory | ||
| STREAMLINE PAY & BENEFITS, LLC | ||
| By: /s/ Bryant J. Reeves, III | ||
| Name: Bryant J. Reeves, III | ||
| Title: Authorized Signatory | ||
| AVELEAD CONSULTING, LLC | ||
| By: /s/ Bryant J. Reeves, III | ||
| Name: Bryant J. Reeves, III | ||
| Title: Authorized Signatory | ||
| STREAMLINE CONSULTING SOLUTIONS, LLC | ||
| By: /s/ Bryant J. Reeves, III | ||
| Name: Bryant J. Reeves, III | ||
| Title: Authorized Signatory | ||
| BANK: | ||
| WESTERN ALLIANCE BANK | ||
| By: /s/ Blake Reid | ||
| Name: Blake Reid | ||
| Title: Senior Director | ||
EXHIBIT B
COMPLIANCE CERTIFICATE
TO: WESTERN ALLIANCE BANK, an Arizona corporation
FROM: Streamline Health Solutions, Inc., a Delaware corporation and Streamline Health, Inc., an Ohio corporation, Streamline Pay & Benefits, LLC, a Delaware limited liability company, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC
The undersigned authorized officer of Borrower hereby certifies that in accordance with the terms and conditions of the Amended and Restated Loan and Security Agreement between Borrower and Bank (the “Agreement”), (i) Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below and (ii) all representations and warranties of Borrower stated in the Agreement are true and correct as of the date hereof. Attached herewith are the required documents supporting the above certification. The Officer further certifies that these are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes.
Please indicate compliance status by circling Yes/No under “Complies” column.
|
Reporting Covenant |
Required |
Complies |
||
|
Annual financial statements (CPA Audited) |
FYE within 180 days |
Yes |
No |
|
|
Monthly financial statements and a Compliance Certificate |
Monthly within 30 days |
Yes |
No |
|
|
10K and 10Q |
(as applicable) |
Yes |
No |
|
|
Annual operating budget, sales projections and operating plans approved by board of directors |
Annually no later than 30 days prior to the beginning of each fiscal year |
Yes |
No |
|
|
A/R & A/P Agings, Borrowing Base Certificate, Deferred Revenue Schedule and Monthly Recurring Revenue Report |
Monthly within 30 days |
Yes |
No |
|
|
A/R Audit |
Initial and Annual |
Yes |
No |
|
|
Deposit balances with Bank |
$ ___________________ |
|||
|
Deposit balance outside Bank |
$ ___________________ |
|||
|
Financial Covenant |
Required |
Actual |
Complies |
|
|
Maximum ARR Net Leverage Ratio |
(a) January 31, 2024, 0.50 to 1.00, (b) April 30, 2024, 0.50 to 1.00, (c) July 31, 2024, 0.45 to 1.00, (d) October 31, 2024, 0.40 to 1.00, and (e) January 31, 2024, 0.35 to 1.00 |
___ to 1.00 |
Yes |
No |
|
Maximum Debt to Adjusted EBITDA Ratio |
(a) April 30, 2025, 3.50 to 1.00, (b) July 31, 2025, 3.00 to 1.00, (c) October 31, 2025, 2.50 to 1.00 and (d) January 31, 2026, and the last day of each quarter thereafter, 2.00 to 1.00 |
___ to 1.00 |
Yes |
No |
|
Fixed Charge Coverage Ratio |
April 30, 2025, and the last date of each quarter thereafter, 1.20 to 1.00 |
___ to 1.00 |
Yes |
No |
|
Minimum Adjusted EBITDA |
(a) January 31, 2024, ($5,750,000), (b) April 30, 2024, ($4,560,000), (c) July 31, 2024, ($2,960,000), (d) October 31, 2024, ($1,500,000) and (e) January 31, 2025, $430,000 |
$_____ |
Yes |
No |
|
Intellectual Property Updates Attached as Exhibit A is a listing of listing of any applications or registrations of intellectual property rights filed with the United States Patent and Trademark Office, including the date of such filing and the registration or application numbers, if any, since the date of the last such Compliance Certificate delivered to Bank. Updates to Schedules Attached as Exhibit A are updated Schedules updating any information set forth in such Schedules since the date of the last such Compliance Certificate delivered to Bank. |
||||
|
Comments Regarding Exceptions: See Attached. |
BANK USE ONLY |
|
|
Received by: |
||
|
Sincerely, |
AUTHORIZED SIGNER |
|
|
Date: |
||
|
__________________________________________ |
Verified: |
|
|
SIGNATURE |
AUTHORIZED SIGNER |
|
|
_________________________________________ |
Date: |
|
|
TITLE |
||
|
Compliance Status |
Yes No |
|
|
___________________________________________ |
||
|
DATE |
||
Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Benjamin Louis Stilwill, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Streamline Health Solutions, Inc.; |
|
|
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
||
|
(b) |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
||
|
(c) |
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
||
|
(d) |
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
(a) |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
||
|
(b) |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: June 12, 2024 |
/s/ Benjamin L. Stilwill |
|
President and Chief Executive Officer |
Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Bryant J. Reeves III, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Streamline Health Solutions, Inc.; |
|
|
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
||
|
(b) |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
||
|
(c) |
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
||
|
(d) |
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
(a) |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
||
|
(b) |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: June 12, 2024 |
/s/ Bryant J. Reeves III |
|
Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Benjamin Louis Stilwill, President and Chief Executive Officer of Streamline Health Solutions, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C Section 1350, that to my knowledge:
|
(1) |
The quarterly report on Form 10-Q of the Company for the quarter ended April 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
||
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition, and results of operations of the Company. |
|
/s/ Benjamin L. Stilwill |
|
|
Benjamin L. Stilwill |
|
|
President and Chief Executive Officer |
|
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Bryant J. Reeves III, Chief Financial Officer of Streamline Health Solutions, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C Section 1350, that to my knowledge:
|
(1) |
The quarterly report on Form 10-Q of the Company for the quarter ended April 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
||
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition, and results of operations of the Company. |
|
/s/ Bryant J. Reeves III |
|
|
Bryant J. Reeves III |
|
|
Chief Financial Officer |
|
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.